SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg12/15/2007 3:47:56 AM
   of 10280
 
$300 Mil.+ Lunesta Account in Play; McCann Defends
December 14, 2007
By Kamau High and Andrew McMains

NEW YORK Sepracor is reviewing U.S. creative duties on its Lunesta sleep aid and incumbent McCann HumanCare is believed to be defending, sources said.

Major media spending on the brand exceeded $330 million last year and totaled nearly $250 million in the first nine months of 2007, according to Nielsen Monitor-Plus.

Interpublic Group's McCann HumanCare is said to be defending against three or four other undisclosed shops. Final presentations are slated for the middle of January. McCann referred calls to the client and the Marlborough, Mass.-based Sepracor did not return calls.

Current ads show a butterfly made of light flying about restfully sleeping people.

In May, Sepracor elevated Adrian Adams, the president and chief operating officer, to the position of president and chief executive officer. Adams replaced Timothy J. Barberich, who was made executive chairman of the board of directors. In October, the company brought in several high level executives including Mark Iwicki, who was formerly vp, cardiovascular business franchise head for Novartis, as evp and chief commercial officer, a newly created position.

Media duties, at IPG's Initiative here, are not believed to be in play.

Sepracor is said to be using Clear Perspectives, a consultant based in Cincinnati, to guide its creative search. Lunesta's competitors include Sanofi-Aventis' Ambien.

adweek.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext